Expression of prospero-related homeobox 1 in breast cancer tissues and its correlation with prognosis

赵东丽; 梁宪斌; 张喜凤; 张维真

doi:10.19401/j.cnki.1007-3639.2019.04.005

您当前的位置：

首页 >

文章列表页 >

Expression of prospero-related homeobox 1 in breast cancer tissues and its correlation with prognosis

更新时间：2026-01-27

- Expression of prospero-related homeobox 1 in breast cancer tissues and its correlation with prognosis
- China Oncology Vol. 29, Issue 4, Pages: 272-276(2019)
- 作者机构：
  
  郑州市第三人民医院肿瘤内一科,河南,郑州,450000
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2019.04.005
  CLC： R737.9
- Published Online：17 May 2019，
  
  Published：17 May 2019
- 稿件说明：
移动端阅览
赵东丽，梁宪斌，王艳，张喜凤，张维真. Prospero相关同源异形盒蛋白1在乳腺癌组织中的表达及与预后相关性分析[J]. 中国癌症杂志, 2019, 29(4): 272-276.

赵东丽, 梁宪斌, 张喜凤, et al. Expression of prospero-related homeobox 1 in breast cancer tissues and its correlation with prognosis[J]. China Oncology, 2019, 29(4): 272-276.
赵东丽，梁宪斌，王艳，张喜凤，张维真. Prospero相关同源异形盒蛋白1在乳腺癌组织中的表达及与预后相关性分析[J]. 中国癌症杂志, 2019, 29(4): 272-276. DOI： 10.19401/j.cnki.1007-3639.2019.04.005.

赵东丽, 梁宪斌, 张喜凤, et al. Expression of prospero-related homeobox 1 in breast cancer tissues and its correlation with prognosis[J]. China Oncology, 2019, 29(4): 272-276. DOI： 10.19401/j.cnki.1007-3639.2019.04.005.

摘要

背景与目的：Prospero相关同源异形盒蛋白1（prospero-related homeobox 1，PROX1）作为同源域转录因子家族成员，参与多种恶性肿瘤的发生、发展过程，与肿瘤细胞增殖、分化、凋亡、迁移和侵袭过程密切相关。该研究探讨了PROX1在乳腺癌组织中的表达及与预后相关性分析。方法：选取2011年3月—2013年3月在郑州市第三人民医院择期行手术治疗且资料完整的乳腺癌患者85例，采用免疫组织化学染色法检测乳腺癌和癌旁组织中PROX1蛋白水平，所有患者术后随访。随访中，失访4例，随访截止日期为2018年3月31日，生存分析采用Kaplan-Meier法和Log-rank检验，乳腺癌患者预后影响因素分析采用Cox比例风险回归模型。结果：乳腺癌组织中PROX1蛋白阳性率为71.76%，癌旁组织则为28.57%，差异有统计学意义（χ

=32.600，P0.001）；乳腺癌组织中PROX1蛋白水平在不同分化程度、TNM分期、雌激素受体（estrogen receptor，ER）、Ki-67标记指数和淋巴结转移患者之间的差异有统计学意义（P0.05）；Kaplan-Meier生存分析结果显示，PROX1阳性表达组平均生存时间为（36.73±2.73）个月，PROX1阴性表达组则为（56.36±2.13）个月，Log-rank检验结果差异有统计学意义（χ

=11.803，P=0.001）；Cox比例风险回归模型结果显示，分化程度、TNM分期、淋巴结转移和PROX1蛋白表达是影响乳腺癌患者预后的风险因素（P0.05）。结论：PROX1蛋白在乳腺癌组织中呈高表达，且与乳腺癌发生、进展及预后密切相关，是影响患者预后的风险因素。

Abstract

Background and purpose: Prospero-related homeobox 1 (PROX1)

a member of the homeodomain transcription factor family

is involved in the development and progression of a variety of malignant tumors

and is closely related to tumo

r cell proliferation

differentiation

apoptosis

migration and invasion. This study explored the expression of PROX1 in breast cancer tissues and its correlation with prognosis. Methods: A total of 85 patients with breast cancer underwent elective surgery

and complete data were collected from Mar. 2011 to Mar. 2013. Immunohistochemical staining was used to detect the protein level of PROX1 in breast cancer and adjacent tissues. All patients were followed up

and 4 patients were lost during follow-up. Follow-up deadline was Mar. 31

2018. Kaplan-Meier method and Log-rank test were used for survival analysis. Cox proportional hazards regression model was used to analyze the prognostic factors of breast cancer. Results: The positive rate of PROX1 protein was 71.76% in breast cancer tissues and 28.57% in adjacent tissues (χ

=32.600

P0.001). The expression of PROX1 protein in breast cancer tissues was significantly different in the degree of differentiation

TNM stage

estrogen receptor (ER)

Ki-67 labeling index and lymph node metastasis compared with adjacent tissues (P0.05). Kaplan-Meier survival analysis showed that the mean survival time of the PROX1 positive expression group was (36.73±2.73) months

and that of the PROX1 negative expression group was (56.36±2.13) months. The Log-rank test howed the difference in mean survival time was statistically significant between the two groups (χ

=11.803

P=0.001). The Cox proportional hazards regression model showed that the degree of differentiation

TNM stage

lymph node metastasis and PROX1 protein expression were risk factors for the prognosis of breast cancer patients (P0.05). Conclusion: PROX1 is highly expressed in breast cancer tissues

and is closely related to the occurrence and progression of breast cancer and prognosis of patients. It is a risk factor affecting the prognosis of patients.

关键词

Keywords

references

Views

1593

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research on the association of breast cancer patients’ prognosis with internal mammary sentinel lymph node biopsy

Receptor discordance between primary breast cancer and liver metastases

Response rate and clinical outcome of HER2-low breast cancer after neoadjuvant therapy: a single-center retrospective study

Internal mammary sentinel lymph node biopsy for breast cancer: a long-term follow-up research for assessment of prognosis and guiding individualized internal mammary lymph node irradiation

Research progress and prospects of neoadjuvant endocrine therapy for breast cancer

Related Author

Ruijie JIA

Zhiqiang SHI

Qi ZHANG

Yongjin LU

Junsheng ZHENG

Jing SUN

Zhao BI

Xiao SUN

Related Institution

Shandong First Medical University Affiliated Tumor Hospital (Shandong Provincial Institute of Cancer Prevention and Treatment, Shandong Cancer Hospital)

Shandong First Medical University (Shandong Provincial Academy of Medical Sciences)

Tianjin Medical University Cancer Institute and Hospital

Phase Ⅰ Clinical Trial Center, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University

AI问答

⁰